DOI QR코드

DOI QR Code

Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers?

  • Kacan, Turgut ;
  • Babacan, Nalan Akgul ;
  • Seker, Metin ;
  • Yucel, Birsen ;
  • Bahceci, Aykut ;
  • Eren, Ayfer Ay ;
  • Eren, Memet Fuat ;
  • Kilickap, Saadettin
  • Published : 2014.03.01

Abstract

Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10%) females, were included in the study. Age (p<0.001) stage (p<0.001), Eastern Cooperative Oncology Group performance status (p<0.001), weight loss (p<0.001), anemia (p<0.001), histopatology (p<0.001), NLR ${\geq}3$ (p=0.048), NLR ${\geq}4$ (p=0.025) and NLR ${\geq}5$ (p=0.018) were found to be the prognostic factors. Age, anemia, Eastern Cooperative Oncology Group performance status, the stage, NLR (${\geq}5$) were an independent prognostic factors. There was a positive correlation between NLR and the Eastern Cooperative Oncology Group performance status (0.23, p=0.001), the C reactive protein levels (r=0.36, p<0.001). Conclusions: Prior to treatment high NLR was found as an independent poor prognosis factor. Besides, NLR correlated with Eastern Cooperative Oncology Group performance status and the C reactive protein levels.

Keywords

Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein

References

  1. Leitch EF, Chakrabarti M, Crozier JE, et al (2007). Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer, 97, 1266-70. https://doi.org/10.1038/sj.bjc.6604027
  2. Kao SC, Pavlakis N, Harvie R, et al (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res, 16, 5805-13. https://doi.org/10.1158/1078-0432.CCR-10-2245
  3. Kasymjanova G, MacDonald N, Agulnik JS, et al (2010). The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol, 17, 52-8.
  4. Kaya V, Yildirim M, Demirpence O, Yildiz M, Yalcin AY (2013). Prognostic significance of basic laboratory methods in non-small-cell-lung cancer. Asian Pac J Cancer Prev, 14, 5473-6. https://doi.org/10.7314/APJCP.2013.14.9.5473
  5. Mano Y, Shirabe K, Yamashita Y, et al (2013). Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg, 258, 301-5. https://doi.org/10.1097/SLA.0b013e318297ad6b
  6. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature, 454, 436-44. https://doi.org/10.1038/nature07205
  7. Martins S, and Pereira JR (1999). Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol, 22, 453-7. https://doi.org/10.1097/00000421-199910000-00006
  8. Mountain CF (1997). Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-17. https://doi.org/10.1378/chest.111.6.1710
  9. Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91. https://doi.org/10.1056/NEJMoa060570
  10. Gore E, Movsas B, Santana-Davila R, Langer C (2012). Evaluation and management of elderly patients with lung cancer. Semin Radiat Oncol, 22, 304-10. https://doi.org/10.1016/j.semradonc.2012.05.007
  11. Gail MH, Eagan RT, Feld R, et al (1984). Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer, 54, 1802-13. https://doi.org/10.1002/1097-0142(19841101)54:9<1802::AID-CNCR2820540908>3.0.CO;2-4
  12. Gondo T, Nakashima J, Ohno Y, et al (2012). Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology, 79, 1085-91. https://doi.org/10.1016/j.urology.2011.11.070
  13. Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2, 706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  14. Halazun KJ, Aldoori A, Malik HZ, et al (2008). Elevated preoperative neutrophil tolymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol, 34, 55-60. https://doi.org/10.1016/j.ejso.2007.02.014
  15. Heikkila K, Ebrahim S, Lawlor DA (2007). A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health, 61, 824-33. https://doi.org/10.1136/jech.2006.051292
  16. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005). Clinical model to predictsurvival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapyregimens based on eastern cooperative oncology group data. J Clin Oncol, 23, 175-83. https://doi.org/10.1200/JCO.2005.04.177
  17. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  18. Chua W, Charles KA, Baracos VE, Clarke SJ (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer, 104, 1288-95. https://doi.org/10.1038/bjc.2011.100
  19. Caglayan B, Fidan A, Salepci B, et al (2004). A. Effects of prognostic factors and treatment on survival in advanced non-small cell lung cancer. Tuberk Toraks, 52, 323-32.
  20. Cedres S, Torrejon D, Martinez A, et al (2012). Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol, 14, 864-9. https://doi.org/10.1007/s12094-012-0872-5
  21. Charloux A, Hedelin G, Dietemann A, et al (1997). Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer, 17, 123-34. https://doi.org/10.1016/S0169-5002(97)00655-7
  22. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
  23. D'Angelo SP, Janjigian YY, Ahye N, et al (2012). Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol, 7, 1815-22. https://doi.org/10.1097/JTO.0b013e31826bb7b2
  24. Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5. https://doi.org/10.7314/APJCP.2013.14.3.2101
  25. Donnem T, Al-Shibli K, Andersen S, et al (2010). Combination of low vascular endothelial growth factor A (VEGF-A)/VEG F receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer, 116, 4318-25. https://doi.org/10.1002/cncr.25333
  26. Ferguson MK, Skosey C, Hoffman PC, Golomb HM (1990). Sex associated differences in presentation and survival in patients with lung cancer. J Clin Oncol, 8, 1402-7.
  27. Shintani Y, Ikeda N, Matsumoto T, et al (2012). Nutritional status of patients undergoing chemoradiotherapy for lung cancer. Asian Cardiovasc Thorac Ann, 20: 172-6. https://doi.org/10.1177/0218492311435249
  28. Schmidt H, Suciu S, Punt CJ, et al (2007). Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol, 25, 1562-69. https://doi.org/10.1200/JCO.2006.09.0274
  29. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R (1996). The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer, 73, 1560-2. https://doi.org/10.1038/bjc.1996.294
  30. Shinkai T, Eguchi K, Sasaki Y, et al (1992). A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemoter Pharmacol, 30, 1-6 https://doi.org/10.1007/BF00686477
  31. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  32. Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127, 978-83. https://doi.org/10.1378/chest.127.3.978
  33. Takahashi T, Sonobe M, Kobayashi M, et al (2010). Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol, 17, 889-97. https://doi.org/10.1245/s10434-009-0808-7
  34. Teramukai S, Kitano T, Kishida Y, et al (2009). Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer, 45, 1950-8. https://doi.org/10.1016/j.ejca.2009.01.023
  35. Albain KS, Swann RS, Rusch VW, et al (2009). Radiotherapy plus chemotherapy with orwithout surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 374, 379-86. https://doi.org/10.1016/S0140-6736(09)60737-6
  36. Riquet M, Bagan P, Le Pimpec Barthes F, et al (2007). Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg, 84, 1818-24. https://doi.org/10.1016/j.athoracsur.2007.07.015
  37. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31. https://doi.org/10.7314/APJCP.2013.14.9.5527
  38. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, DonnenbergVS (2011). Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother, 60, 819-27. https://doi.org/10.1007/s00262-011-0996-4
  39. Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol, 13, 1221-30
  40. Roxburgh CS, McMillan DC (2010). Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol, 6, 149-63. https://doi.org/10.2217/fon.09.136
  41. Sanchez-Lara K, Turcott JG, Juarez E, et al (2012). Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer, 64, 526-34. https://doi.org/10.1080/01635581.2012.668744
  42. Sarraf KM, Belcher E, Raevsky E, et al (2009). Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg, 137, 425-8. https://doi.org/10.1016/j.jtcvs.2008.05.046
  43. Schmidt H, Bastholt L, Geertsen P, et al (2005). Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer, 93, 273-8. https://doi.org/10.1038/sj.bjc.6602702
  44. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005). Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. https://doi.org/10.1002/jso.20329
  45. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  46. Uslu AU, Deveci K, Korkmaz S, et al (2013). Is neutrophil/lymphocyte ratio associated with subclinical inflammation and amyloidosis in patients with familial mediterranean Fever? Biomed Res Int, 185317, pages 5.
  47. Vaupel P, Thews O, Hoeckel M (2001). Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol, 18, 243-59. https://doi.org/10.1385/MO:18:4:243
  48. Wigren T (1997). Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol, 44, 9-15. https://doi.org/10.1016/S0167-8140(97)00087-X
  49. Yao Y, Yuan D, Liu H, Gu X, Song Y (2013). Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother, 62, 471-9. https://doi.org/10.1007/s00262-012-1347-9
  50. Yucel B, Babacan NA, Kacan T, et al (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev, 14, 6687-92. https://doi.org/10.7314/APJCP.2013.14.11.6687
  51. Zhang J, Huang SH, Li H, et al (2013). Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Med Oncol, 30, 352. https://doi.org/10.1007/s12032-012-0352-3

Cited by

  1. Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4781
  2. Elevated Neutrophil-to-Lymphocyte Ratio in Squamous Cell Carcinoma of Larynx Compared to Benign and Precancerous Laryngeal Lesions vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7351
  3. Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3997
  4. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis vol.5, pp.1, 2015, https://doi.org/10.1038/srep12493
  5. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients vol.6, pp.3, 2015, https://doi.org/10.1111/1759-7714.12178
  6. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer vol.11, pp.10, 2016, https://doi.org/10.1371/journal.pone.0163397
  7. Neutrophil/lymphocyte ratio has a prognostic value for patients with terminal cancer vol.14, pp.1, 2016, https://doi.org/10.1186/s12957-016-0904-7
  8. Mean Platelet Volume, Red Cell Distribution Width, and Neutrophil-to-Lymphocyte Ratio Before and After Surgery in Patients With Carotid Body Tumors vol.28, pp.7, 2017, https://doi.org/10.1097/SCS.0000000000003786
  9. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection vol.96, pp.5, 2017, https://doi.org/10.1097/MD.0000000000005935
  10. Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4230-z